WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s participation at the following healthcare investor conferences: Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, […]
Day: November 7, 2024
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s participation at the following healthcare investor conferences: Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, […]
ATNi Launches 5th Global Access to Nutrition Index as Industry and Policy Makers Grapple with Food Polycrisis
UTRECHT, The Netherlands, Nov. 07, 2024 (GLOBE NEWSWIRE) — Today, ATNi launches the 5th edition of the Global Access to Nutrition Index, the largest yet, assessing the world’s 30 largest food and beverage manufacturers and over 52,000 products, representing 23% global market share. One in five deaths globally is associated with a poor diet. One out […]
MLL Legal Selects Anaqua’s AQX Law Firm Platform to Enhance IP Management and Drive Operational Efficiency
Leading Swiss law firm adopts scalable, intuitive solution to strengthen IP management capabilities BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) — Anaqua, the leading provider of innovation and intellectual property (IP) management technology, today announced that MLL Legal, one of Switzerland’s largest law firms, has selected Anaqua’s AQX® Law Firm platform to enhance its IP management capabilities for […]
Nyxoah Reports Third Quarter Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports Third Quarter Financial and Operating Results FDA approval on track for first quarter 2025, U.S. commercial team build out in progress Company fully funded with cash until mid 2026 Mont-Saint-Guibert, Belgium – November 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the third quarter of 2024. Recent Financial and Operating Highlights Presented compelling DREAM data results at International Surgical Sleep Society in September. Raised €24.6 million through an ATM program from […]